Frank, this is just another American Leftwing Lynching of a prominent black conservative. Disgusting to a degree which the left will have to pay a price for their uniquely specialized black conservative attack.
And if the Republican establishment had anything to do with this witch hunt and lynching, they must pay a price as well.
Conservatives are watching...
halftrack, I would expect a comment like that from a guy that hears of a Muslim American lopping of a coworkers head, and you call it workplace violence only.
Because beheadings at work happen all the time in America. Oh wait, they never happen, except the one time, due to workplace violence. You know, much like Nidal Malik Hasan in Fort Hood. Workplace violence.
We sure are seeing a lot of workplace violence in the middle east, that seems to be spreading around the world.
Yes bcrx we know you don't care about Celldex or the truth about Celldex, or the truth about Republicans or Democrats. Just a leftist short basher doing what you do.
""Our data show that CD27 modulation through varlilumab results in immune activation and suppression of Treg activity, either of which can be independently responsible for a therapeutic effect, depending on the cancer model," said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. "Because individual human cancers are also likely to have different sensitivities to these anti-tumor activities, varlilumab's ability to act through both mechanisms provides the broadest potential for therapeutic benefit. Our collection of preclinical and clinical results to date support Celldex's broad clinical development program across tumor types and in combinations with other anti-tumor agents."
To better understand each mechanism separately, scientists engineered varlilumab to possess either strong co-stimulatory activity (varli-mG1) or strong Treg suppression activity (varli-mG2a) and analyzed their efficacy in several preclinical tumor models. The data indicated that potent co-stimulation activity was required for therapeutic activity in a BCL1 lymphoma model, whereas control of Tregs was required for activity in several other models, such as E.G7 thymoma, CT26 colorectal and colon 26. Importantly, varlilumab has a combination of immune co-stimulation and Treg depleting activity and demonstrated potent anti-tumor activity in all the models."
No doubt there are higher standards and double standards applied by the leftist media when questioning Republicans vs Democrats. The handling of Obama and HRC vs Carson are glaring examples; however, Ben Carson's written story on West Point is not fully accurate. Sounds like he did meet with Westmoreland, did discuss entering West Point as an option, was told he could, and would likely get in, but never did actually apply, so was not actually offered a scholarship. Sounds like he conflated the discussion with Westmoreland and subsequent discussions of with his ROTC teacher, as an offer from West Point.
I'm sure he thought he basically had an offer after speaking with the General, and I am sure West Point would have extended the scholarship, but that won't do in presidential politics. I give this episode a (half truth), but the leftist will call it a complete lie. Now, if we can get them to apply the same standards to Hillary Clinton.
Carson will need to personally answer these charges, and omissions of material and relevant facts in his West Point story scholarship, no scholarship story. And hope like heck no other half truths are out there.
Can we now talk about HRC's non disclosure document signature?
How does that help the environment? Or energy independence? You want oil from the middle east?
Now they will ship that oil to China. That is good for the environment?
Varli did what is was suppose to do. So I agree with you neshua. We learn with each trial, what works and what does not. ONT-10 is being shelved, not Varli.
Actually, most of those jobs were in the financial, and medical sector. Manufacturing is not growing. You are seeing a direct effect of government intervention through easy money policy, and free healthcare for a large sector of the population, which staffing was sure to follow. Eventually this bubble will pop, only so much of other peoples money to go around.
"Although a small proportion of total employment, manufacturing has been one source of weakness, losing more than 25,000 jobs over the summer amid softening demand from Asia and other export markets. The mining and logging sector has also been shedding jobs, cutting more than 100,000 positions this year as prices of oil, iron and other commodities have plunged.
Still, many other areas of the economy — like professional and business services, health care, and leisure and hospitality — have been very strong, with employment in each of those three sectors increasing by more than 30,000 jobs in September.
The pattern persisted in October: Factory jobs were unchanged, while mining and logging lost 4,000 positions. Professional and business services, meanwhile, recorded a huge 78,000 increase in jobs. Health care hiring was also robust, with a 56,700 increase."
"Oncothyreon recently completed evaluation of two dosing cohorts in the Oncothyreon-led Phase 1b trial of ONT-10, a therapeutic vaccine targeting the tumor-associated antigen MUC1, in combination with varlilumab in patients with advanced breast and ovarian cancers. Preliminary data from these two cohorts did not demonstrate sufficient activity to move forward with the program, and Oncothyreon does not plan to enroll additional patients in the Phase 1b trial. Varlilumab biomarker analyses from peripheral blood samples from this study are consistent with prior experience including an increase in activated T cells and natural killer cells and a decrease in regulatory T cells. "
But still disappointing. Would like to hear more analysis and opinion of this from Celldex on this.
"The Company will present an update on overall survival and long-term survival in a podium presentation at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on Friday, November 20 th at 1:30 PM CT/2:30 PM ET."
It's never quite what you say it is, cujo. The news was both good and bad.
"Patients with non-β0/β0 and β0/βE genotypes, the less severe types of beta-thalassemia major, appear to be cured with LentiGlobin BB305. Every patient that has been treated remains transfusion-free.
Patients with the β0/β0 genotype, who have no hemoglobin production, haven't been as fortunate. Two patients with the genotype have received a single transfusion since getting the LentiGlobin BB305 treatment. Another patient with the genotype hasn't been able to stop receiving transfusions post treatment.
Now what: All of this data from the abstracts is as of July 31, so the data presented at ASH next month will contain more up to date information. Longer follow up times could bring good news for the less severe genotypes since the longer they remain transfusion-free the more likely the treatment is truly a cure. For the β0/β0 genotype, the situation probably isn't going to get better, and LentiGlobin BB305 may not be a cure. Depending on how much the treatment improves patients' lives by reducing the number of transfusions, LentiGlobin BB305 could still be a viable treatment for the β0/β0 genotype."